Extract
Erythrocyte abnormalities have been demonstrated to be associated with increased risk of cardiovascular disease development and severity, affecting morbidity and mortality [1, 2].
Abstract
Erythrocytes display structural and functional intrinsic defects in patients with pulmonary arterial hypertension. Their clinical relevance as potential biomarkers and their contribution in the disease pathophysiology still need to be defined. https://bit.ly/3iDYFOe
Acknowledgements
The authors acknowledge Yannaëlle Rousseau for her help in this study.
Footnotes
Conflict of interest: E-M. Jutant, L. Tu, R. Thuillet, V. Picard and A. Huertas have no conflicts of interest to disclose. C. Guignabert reports grants from Acceleron, Janssen, ShouTi and MSD to his institution, and personal fees from MSD. F. Parent reports grants from Acceleron, Bayer, Merck and Janssen to her institution, and personal fees from Bayer and MSD, outside the submitted work. O. Sitbon reports grants to his institution from Janssen, Bayer, MSD and GSK, and personal fees from Janssen, MSD, Acceleron, Gossamer Bio, Bayer, Ferrer, AOP Orphan and GSK. M. Humbert reports grants to his institution and personal fees from Acceleron, Janssen and Merck, and personal fees from AOP, Acceleron, Janssen and Merck, outside the submitted work. L. Savale reports grants to his institution and personal fees from Acceleron, Janssen and Merck, and personal fees from Bayer, Janssen and Merck, outside the submitted work.
Support statement: This research was supported by ERS Main Award in Novel Research in Pulmonary Arterial Hypertension 2020 awarded to A. Huertas.
- Received September 20, 2021.
- Accepted March 20, 2022.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org